Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of ASP7657 in Healthy Subjects
NCT02108548Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Apr 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP7657 in pain and inflammation (7 arms), sponsored by Astellas Pharma. Primary endpoint: Safety assessed by adverse events, vital signs, laboratory tests, electrocardiogram (ECGs), collagen and adenosine diphosphate (ADP)-induced platelet aggregation, and gastrointestinal (GI) safety… Started Apr 2014; status: terminated.
02
Drugs
ASP7657
03
Conditions
paininflammation
Beyond the preview
Go deeper on NCT02108548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108548.